Información del artículo
El Texto completo está disponible en PDF
References
[1.]
A. Sardella.
An up-to-date view on burning mouth syndrome.
Minerva Stomatol, 56 (2007), pp. 327-340
[2.]
J.M. Zakrzewska, H. Forssell, M. Glenny.
Interventions for the treatment of burning mouth syndrome.
Cochrane Database Syst Rev, 25 (2005),
[3.]
M.P. Mínguez Serra, C. Salort Llorca, F.J. Silvestre Donat.
Pharmacological treatment of burning mouth syndrome: A review and update.
Med Oral Patol Oral Cir Bucal, 12 (2007), pp. 299-304
[4.]
T.S. Foster.
Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy.
Diabetes Educ, 33 (2007), pp. 111-117
[5.]
F. Fermiano, F. Gombos, C. Scully.
Burning mouth syndrome: the efficacy of lipoic acid on subgroups.
J Eur Acad Dermatol Venereol, 18 (2004), pp. 676-678
[6.]
F. Fermiano, F. Gombos, C. Scully.
Burning Mouth Syndrome: open trial of psychotherapy alone, medication with alphalipoic acid (thioctic acid), and combination therapy.
Med Oral, 9 (2004), pp. 8-13
[7.]
F. Fermiano, C. Scully, F. Gombos.
Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy.
Int J Oral Maxillofac Surg, 31 (2002), pp. 625-628
[8.]
F. Fermiano.
Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies.
Minerva Stomatol, 51 (2002), pp. 405-409
[9.]
F. Fermiano, C. Scully.
Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy.
J Oral Pathol Med, 31 (2002), pp. 267-269
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
